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Sprague Dawley rats were exposed via inhalation to vapor condensates of either gasoline or gasoline
combined with various fuel oxygenates to assess whether their use in gasoline inﬂuences the hazard
of evaporative emissions. Test substances included vapor condensates prepared from an EPA described
‘‘baseline gasoline’’ (BGVC), or gasoline combined with methyl tertiary butyl ether (G/MTBE), ethyl
t-butyl ether (G/ETBE), t-amyl methyl ether (G/TAME), diisopropyl ether (G/DIPE), ethanol (G/EtOH),
or t-butyl alcohol (G/TBA). Target concentrations were 0, 2000, 10,000 or 20,000 mg/m3 and exposures
were for 6 h/day, 5 days/week for 13 weeks. A portion of the animals were maintained for a four week
recovery period to determine the reversibility of potential adverse effects. Increased kidney weight and
light hydrocarbon nephropathy (LHN) were observed in treated male rats in all studies which were
reversible or nearly reversible after 4 weeks recovery. LHN is unique to male rats and is not relevant
to human toxicity. The no observed effect level (NOAEL) in all studies was 10,000 mg/m3, except for
G/MTBE (<2000) and G/TBA (2000). The results provide evidence that use of the studied oxygenates
are unlikely to increase the hazard of evaporative emissions during refueling, compared to those from
gasoline alone.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The 1990 amendments to the Clean Air Act (CAA) mandated
the use of oxygenates in motor gasoline. In 1994, the U.S. Envi-
ronmental Protection Agency (EPA) issued a ﬁnal rule under the
Act which added new health effects information and testing
requirements to the Agency’s existing registration requirements.
As described in more detail in a companion paper (Henley
et al., 2014), requirements include inhalation exposures to
evaporative emissions of the gasoline or additive in question.
The health endpoints include assessments for standard sub-
chronic toxicity, neurotoxicity, genotoxicity, immunotoxicity,developmental and reproductive toxicity, and chronic toxicity/
carcinogenicity. The results of chronic toxicity testing of gasoline
and gasoline combined with MTBE have already been reported
(Benson et al., 2011) and reported elsewhere in this issue are
the ﬁndings for genotoxicity (Schreiner et al., 2014), neurotoxicity
(O’Callaghan et al., 2014), immunotoxicity (White et al., 2014),
reproductive toxicity (Gray et al., 2014), and developmental tox-
icity testing in mice and rats (Roberts et al., 2014a,b). This paper
describes the results of subchronic toxicity testing submitted to
EPA.
Test substances evaluated in the 13 week toxicity studies
included vapor condensates prepared from an EPA deﬁned ‘‘base-
line gasoline’’ (BGVC), as well as gasoline combined with methyl
tertiary butyl ether (G/MTBE), ethyl t-butyl ether (G/ETBE), t-amyl
methyl ether (G/TAME), diisopropyl ether (G/DIPE), ethanol (G/
EtOH), or t-butyl alcohol (G/TBA). The goal of the studies was to
provide information on the extent to which the use of oxygenates
in gasoline might alter the hazard of evaporative emissions that are
encountered during refueling of vehicles, compared to those from
gasoline alone.
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2.1. Test substance preparation and characterization
Gasoline and gasoline/oxygenate vapor condensates were pre-
pared and supplied in 100 gallon gas cylinders by Chevron
Research and Technology Center (Richmond, CA). Since only 5-gal-
lon cylinders were practical for use in exposure operations, the test
substance was dispensed as needed at the testing facility from the
100 gallon cylinders into 5-gallon cylinders using nitrogen pressur-
ization. The methodology for preparation and analytical character-
ization of the samples is described in a companion paper (Henley
et al., 2014). Test substances included vapor condensates prepared
from an EPA described ‘‘baseline gasoline’’ (BGVC), identiﬁed as API
Lot 99-01, and gasoline combined with methyl tertiary butyl ether
(G/MTBE), ethyl t-butyl ether (G/ETBE), t-amyl methyl ether (G/
TAME), diisopropyl ether (G/DIPE), ethanol (G/EtOH), or t-butyl
alcohol (G/TBA).2.2. Experimental design
Seven separate 13-week inhalation toxicity studies were con-
ducted of gasoline and gasoline/oxygenate vapor condensates at
Huntingdon Life Sciences (East Millstone, NJ). In each of these stud-
ies, a total of 120 animals were used in the main and recovery
phases (Table 1) and an additional 160 animals were used in satel-
lite studies to more closely evaluate neurotoxicity, immunotoxicity
and genotoxicity (Table 2). The exposure initiation dates for the
studies were: BGVC – September 13, 2000; G/MTBE – February 6,
2001; G/EtOH – April 17, 2001; G/TAME – June 26, 2001; G/ETBE
– October 23, 2001; G/DIPE – February 12, 2002; and G/TBA – June
25, 2002.
After 13 weeks of exposure, 20 control and 20 high dose ani-
mals were kept unexposed for an additional 4 weeks to serve as
a recovery group. Clinical chemistry, coagulation and hematology
evaluations were conducted on ten males and females per treat-
ment group after 4 and 13 weeks of exposure as well as on the
recovery group at the end of the recovery period. Necropsies were
conducted on 10 male and 10 female animals per exposure group
at the end of 13 weeks, and on all of the recovery group animals
consisting of 10 male and 10 female animals in the control and
high concentration groups.2.3. Animal selection, assignment and care
CD (Sprague–Dawley derived) [Crl: CD@ IGS BR] albino rats
(approximately 6 weeks old) were received from Charles River Lab-
oratories (Kingston, NY) for each study. Animals were acclimated
for at least 16 days after receipt and examined to conﬁrm suitabil-
ity for study.Table 1
Main and recovery study design.
Main study Main and recovery study an
Number of animals at initiat
Exposure group Target concentration (mg/m3)
M F
Control 0 (air only) 20 2
Low 2000 10 1
Middle 10,000 10 1
High 20,000 20 2
a Exposures were 6 h/day, generally 5 days/week for 13 weeks, for at least 65 exposu
b Complete postmortem evaluations were performed on animals.Each rat was assigned a temporary number upon receipt and
then identiﬁed with a metal ear tag bearing its assigned animal
number. The assigned animal number plus the study number com-
prised the unique animal number for each animal. In addition, each
cage was provided with a cage card, which was color-coded for
exposure level identiﬁcation and contained study number and ani-
mal number information.
Animals considered suitable for study on the basis of pretest
physical examinations, body weight data and pretest ophthalmol-
ogy evaluations were randomly assigned, by sex, to control or trea-
ted groups in an attempt to equalize mean group body weights.
Individual weights of animals placed on test were within ±20% of
the mean weight for each sex for each study. Currently acceptable
practices of good animal husbandry were followed (National
Academy of Sciences, 1996). Huntingdon Life Sciences, East Mill-
stone, NJ is fully accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC).
2.4. Diet and drinking water
Certiﬁed Rodent Diet, No. 5002; (Meal) (PMI Nutrition Interna-
tional, St. Louis, MO) was available without restriction, except dur-
ing exposures. Fresh feed was presented weekly. Analysis of each
feed lot used during this study was performed by the manufac-
turer. There were no known contaminants in the feed which were
expected to interfere with the results of this study. Water was
available without restriction via an automated watering system,
except during exposures. Monthly water analyses are conducted
by Elizabethtown Water Company, Westﬁeld, NJ (Raritan-Mill-
stone Plant). In addition, water samples were collected biannually
from representative rooms in the testing facility for microbiologi-
cal analyses by a subcontract laboratory. There were no known
contaminants in the water which were expected to interfere with
the results of this study.
2.5. Housing and environmental conditions
Animals were housed individually in suspended stainless steel
wire mesh cages. During exposure periods, animals were individu-
ally housed in stainless steel, wire mesh cages within a 1000 L
stainless steel and glass whole-body exposure chamber. A twelve
hour light/dark cycle controlled via an automatic timer was pro-
vided. Temperature and relative humidity were monitored in
accordance with Testing Facility SOPs and maintained within the
speciﬁed range (18–26 degrees C, and 30–70%, respectively) to
the maximum extent possible. Excursions outside the speciﬁed
range were not considered to have affected the integrity of the
study.
During exposure periods chamber static pressure was recorded
every half-hour. Chamber temperature and relative humidity wereimals
ion of exposurea Necropsy and microscopic pathologyb
Terminal (13 weeks) After 4 weeks recovery
M F M F
0 10 10 10 10
0 10 10 – –
0 10 10 – –
0 10 10 10 10
res.
Table 2
Satellite studies conducted.
Satellite studies Number of animals at initiation of exposurea Number of animals used in satellite studies
Exposure group Target concentration (mg/m3) Neuropathologya GFAPa Immunotoxicityb Genotoxicityb
M F M F M F M F
Control 0 (air only) 15 25 5 5 5 5 0 10 5 5
Low 2000 15 25 5 5 5 5 0 10 5 5
Middle 10,000 15 25 5 5 5 5 0 10 5 5
High 20,000 15 25 5 5 5 5 0 10 5 5
a Exposures were 6 h/day, 5 days/week for 13 weeks, for at least 65 exposures for Neuropathology and GFAP studies. Neurobehavioral studies (functional observational
battery and motor activity) were performed on the animals in these studies.
b Exposures were 6 h/day, generally 5 days/week for 4 weeks for 20 exposure for Genotoxicity and Immunotoxicity studies.
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maximum extent possible, within the target ranges (20–24 degrees
C and 40–60%, respectively). Excursions outside the speciﬁed range
were not considered to have affected the integrity of the study.
Chamber oxygen levels (maintained at least 19%) were measured
pretest and at the beginning, middle and end of the study. Air sam-
ples were taken in the vapor generation area pretest and at the
beginning, middle and end of the study. Light (maintained approx-
imately 30–40 foot-candles at 1.0 m above the ﬂoor) and noise lev-
els (maintained below 85 decibels) in the exposure room were
measured pretest and at the beginning, middle and end of the
study.
2.6. Test substance administration
The test substance was administered as a vapor in the breathing
air of the animals. The test atmosphere was generated by an appro-
priate procedure determined during pre-study trials. The trials
were performed to evaluate the optimal set of conditions and
equipment to generate a stable atmosphere at the target exposure
levels and maintain uniform conditions throughout the exposure
chambers. Two chambers were used for each exposure level, in
general one for male animals and one for female animals, with
the placement of the animals in the whole-body exposure cham-
bers rotated weekly to ensure uniform exposure of the animals.
The test substance was administered for 6 h/day, generally
5 days per week for 13 weeks for at least 65 exposures for main
study and recovery animals. Test substance administration contin-
ued through the day prior to necropsy for all animals except the
animals in the control and high concentration groups designated
for recovery which were held untreated for at least 4 additional
weeks prior to necropsy.
2.7. Exposure chamber operation
Unexposed control group – Houseline nitrogen was delivered
from a regulator with a backpressure gauge via 1/400 tubing to a
ﬂow meter regulated by a metering valve (Fig. 1). This nitrogen
ﬂow was then split via a 1/400 stainless steel ‘‘T’’ to both chamber
turrets of the 1 cubic meter glass and stainless steel exposure
chamber where it was mixed with room air as it was drawn into
the chamber.
Low, middle and high exposure groups – Houseline nitrogen was
delivered from a regulator with a backpressure gauge through a
stainless steel ﬁtting to create three ﬂow systems: the test sub-
stance pressurization ﬂow, the purge ﬂow and the volatilization
ﬂow.
The nitrogen for the test substance pressurization ﬂow was
directed through a metering valve, attached to a back pressure
gauge, into the vapor inlet valve of the test substance cylinder.
The metering valve was used to adjust and maintain the pressure
within the cylinder. From the pressurized cylinder, the testsubstance ﬂowed from the liquid outlet valve through a disconnect
ﬁtting (equipped with a toggle valve) and through a ﬁlter to pre-
vent equipment contamination. From the ﬁlter, the test substance
ﬂowed to a liquid ﬂow meter via 1/800 tubing. The outlet of the ﬂow
meter was regulated by a metering valve. From this metering
valve, the test substance ﬂowed via 1/800 tubing onto the glass helix
of a counter current volatilization chamber. This glass helix was
heated by a nichrome wire which was controlled by a variable
autotransformer and inserted in the center of the glass tube that
supported the helix external to the volatilization chamber.
The nitrogen for the purge ﬂow system was directed, via 1/400
tubing to a ﬂow meter regulated by a metering valve. The purge
nitrogen was delivered via 1/800 tubing to the bottom of the tube
containing the nichrome wire. This nitrogen ﬂow continuously
purged the area surrounding the nichrome wire within the tube,
thereby, protecting the wire from oxidation.
The nitrogen for the volatilization system was directed via 1/400
tubing to a ﬂow meter regulated by a metering valve. From the
ﬂow meter, the volatilization nitrogen ﬂowed via 1/400 tubing to a
ball and socket joint at the bottom of the volatilization chamber.
This nitrogen ﬂowed up through the volatilization chamber pass-
ing over the coil and volatilizing the test substance. The pressure
within the counter-current volatilization chamber was maintained
slightly negative to the room and was monitored with a pressure
gauge.
This test substance ladennitrogen exited the top of the volatiliza-
tion chamber through a stainless steel ‘‘T’’ which divided the ﬂow,
via 1/200 tubing, to the turrets of two1 cubicmeter glass and stainless
steel exposure chambers. As the test substance laden nitrogen was
drawn into each of the chambers, it was mixed with room air.
The whole-body exposure chambers each had a volume of
approximately 1000 L (l m3). Each chamber was operated at a min-
imum ﬂow rate of 200 L/min. The ﬁnal airﬂow was set to provide at
least one air change (calculated by dividing the chamber volume
by the airﬂow rate) in 5.0 min (12 air changes/h) and a T99 equilib-
rium time (calculated by multiplying the air change by the expo-
nential factor 4.6) of at most 23 min.
This chamber size and airﬂow rate was considered adequate to
maintain the oxygen level at least 19% and the animal loading fac-
tor below 5%. At the end of each exposure, all animals remained in
the chamber for a minimum of 30 min. During this time, each
chamber was operated at approximately the same ﬂow rate using
clean air only. The chambers were exhausted through the in house
ﬁltering system, which consisted of a coarse ﬁlter, a HEPA ﬁlter,
activated charcoal and then through a fume incinerator.
2.8. Exposure concentration determination
A nominal exposure concentration was calculated. The ﬂow of
air through the chamber was monitored using appropriate cali-
brated equipment. The test substance consumed (weight differ-
ence of the 5 gallon cylinder) during the exposure (mg) was
Fig. 1. Exposure and air sampling methodology: two chambers (designated chambers A and B) were used for each exposure level, in general one for male animals and one for
female animals. During each exposure, measurements of airborne concentrations were performed in the animals’ breathing zone at least 4 times using an infrared (IR)
spectrophotometric analytical procedure. Also, one charcoal tube sample was collected per chamber per week and analyzed by gas chromatography (GC) to characterize at
least 10 major components (comprising at least 80% by weight of the test substance) to show test substance stability and comparison between the neat liquid test substance
and the vaporized test atmospheres.
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chamber (volumetric combined ﬂow rate for the 2 chambers
times total exposure time) to calculate the nominal concentration
mg/m3).
During each exposure, measurements of airborne concentra-
tions were performed in the animals’ breathing zone at least 4
times using an appropriate sampling procedure and infrared (IR)
spectrophotometric analytical procedure. Also, one charcoal tube
sample was collected per chamber per week and analyzed by gas
chromatography (GC) to characterize at least 18 major components
(comprising at least 80% by weight of the test substance) to show
test substance stability and comparison between the neat liquid
test substance and the vaporized test atmospheres.
During each week of exposure, particle size determinations
were performed using a TSI Aerodynamic Particle Sizer to charac-
terize the aerodynamic particle size distribution of any aerosol
present. The samples were drawn for 20 s at a ﬂow rate of
5.00 L/min. The mass median aerodynamic diameter, geometric
standard deviation and total mass concentration were calculated
based on the amount of particles collected.2.9. Experimental observations and evaluations
Animals were observed in their cages twice daily for mortality
and signs of severe toxic or pharmacologic effects. Animals in
extremely poor health or in a possible moribund condition were
identiﬁed for further monitoring and possible euthanasia. All ani-
mals were observed as a group at least once during each exposure.
Each animal was removed from its cage and examined twice pre-
test and once weekly during the study period. Examinations
included observations of general condition, skin and fur, eyes, nose,
oral cavity, abdomen and external genitalia as well as evaluations
of respiration, palpation for tissue masses, circulatory effects,autonomic effects, central nervous system effects, changes in
motor activity, and reactivity to handling or sensory stimuli. Animals
were also removed from their cages and weighed twice pretest,
weekly during treatment and terminally (after fasting). Terminal,
fasted body weights were obtained just prior to necropsy.
Food consumption was measured (weighed) during the week
prior to treatment initiation and weekly throughout the study.
Feed was available without restriction 7 days/week except during
inhalation exposures and when fasting prior to blood collection.
Animals were presented with weighed feeders at the scheduled
intervals. After 7 days (4 days during the 400 week of the recovery
period), the feeders were reweighed and the resulting weight sub-
tracted from the initial feeder weight to obtain the grams of feed
consumed per animal per week. The grams consumed per kilogram
of body weight per day was then calculated for each animal.
All animals received ophthalmoscopic examinations pretest and
at study termination. Eyelids, lacrimal apparatus and conjunctiva
were examined grossly; cornea, anterior chamber, lens, vitreous
humor, retina and optic disc were examined by indirect ophthal-
moscopy. The eyes were examined after instillation of a mydriatic
solution (Mydriacyl 1%).2.10. Clinical pathology
Clinical pathology procedures and parameters were based on
those recommended in guidelines published by the Joint Scientiﬁc
Committee for International Harmonization of Clinical Pathology
Testing (Weigand et al., 1996). Blood was obtained from lightly
anesthetized (carbon dioxide/oxygen, 60/40%) animals via punc-
ture of the orbital sinus (retrobulbar). Rats were fasted overnight
prior to blood collection. The Main Study animals were bled at
the Interim (4 weeks) and Terminal intervals.
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Blood for hematology studies was collected (approximately
0.25 mL) into tubes containing EDTA anticoagulant. Blood samples
were analyzed for: hemoglobin concentration, hematocrit, erythro-
cyte count, platelet count, mean corpuscular volume, mean corpus-
cular hemoglobin, mean corpuscular hemoglobin concentration,
total leukocyte count, reticulocyte count, differential leukocyte
count, and erythrocyte morphology.2.12. Coagulation studies
Blood for coagulation studies was collected (approximately
1.0 mL) into tubes containing sodium citrate anticoagulant. Blood
samples were analyzed with Mechanical clot detection system
(STA compacta, Diagnostica Stago Products) for prothrombin time
and activated partial thromboplastin time.2.13. Clinical chemistry
Blood for clinical chemistry studies was collected (approxi-
mately 1.5 mL except 1.0 mL for the female animals at the 4th
week interval) into tubes with no anticoagulant, allowed to clot,
and centrifuged to obtain serum. Blood samples were analyzed
with a Hitachi 717 automatic analyzer (Roche Corporation) for
aspartate aminotransferase, alanine aminotransferase, alkaline
phosphatase, lactate dehydrogenase, sorbitol dehydrogenase,
blood urea nitrogen, creatinine, glucose, creatine kinase, choles-
terol, albumin, total bilirubin, direct bilirubin, sodium, potassium,
chloride, calcium, inorganic phosphorus, gamma-glutamyl trans-
ferase, bile acids, globulin, albumen/globulin ratio, and indirect
bilirubin.2.14. Postmortem evaluations
Animals were fasted overnight prior to necropsy and eutha-
nized by exsanguination following carbon dioxide inhalation for
main study and recovery animals. A necropsy schedule was estab-
lished to ensure that approximately equal numbers of males and
females were examined on each day of necropsy and that examina-
tion of animals of both sexes were performed at similar times of
the day throughout the necropsy period.2.15. Macroscopic examinations
Katherine M. Whitney, DVM, PhD was the pathologist for all of
the studies, and had oversight responsibility for the gross and
microscopic pathology aspects of the studies. Complete macro-
scopic postmortem examinations were performed on all main
study and recovery animals. Animals that were humanely sacri-
ﬁced or were found dead in satellite studies also received a macro-
scopic examination, which included examination of the external
surface and all oriﬁces; the external surfaces of the brain and spinal
cord; the organs and tissues of the cranial, thoracic, abdominal and
pelvic cavities and neck; and the remainder of the carcass for the
presence of macroscopic morphologic abnormalities.
The organs indicated in Table 3 were weighed for all main study
and recovery animals during the scheduled necropsy. Prior to
recording weights, the organs were carefully dissected and prop-
erly trimmed to remove adipose and other contiguous tissues in
a uniform manner. Organs were weighed as soon as possible after
dissection in order to avoid drying. Paired organs were weighed
together.2.16. Histopathologic examinations
Tissues shown in Table 3 were excised at the scheduled sacriﬁce
intervals and preserved for all ‘‘main’’ and ‘‘recovery study’’ ani-
mals. In addition, slides of the tissues were prepared and examined
microscopically for all main study animals. Any abnormalities not
noted during macroscopic examinations which were seen during
histology processing were recorded. Screening for alpha 2u-globu-
lin nephropathy: A preliminary diagnosis was made on hematoxy-
lin and eosin stained slides of the kidney and/or based on elevated
kidney weights at the terminal sacriﬁce. The sections were then
stained with Mallory Heidenhain stain (Sheehan and Hrapchak,
1987) since the following lesions were seen with H&E: angular
hyaline inclusions in the proximal convoluted tubule, tubular
degeneration and regeneration, and/or globular casts at the cor-
tico-medullary junction in the BGVC and G/MTBE studies.
All retained tissues were preserved in 10% neutral buffered for-
malin. Eyes were placed in glutaraldehyde/paraformaldehyde ini-
tially and then retained in 10% formalin. Testes and epididymides
were placed in Modiﬁed Davidson’s solution and then retained in
10% neutral buffered formalin. Lungs and urinary bladders were
infused with formalin prior to their immersion into a larger volume
of the same ﬁxative. After ﬁxation, the tissues and organs from all
animals were routinely processed, embedded in parafﬁn, cut at a
microtome setting of 4–7 microns, mounted on glass slides, stained
with hematoxylin and eosin and examined by light microscopy.
The bones were decalciﬁed in Decalciﬁer™.2.17. Statistical analysis
Statistical analyses were conducted on mean body weight val-
ues and body weight changes (from pretest), mean feed consump-
tion values (presented as grams of feed/kg of body weight per day),
mean clinical laboratory values, mean organ weights, organ-to-
body weight ratios, and organ-to-brain weight ratios. Mean values
of all exposure groups were compared to the mean value for the
control group at each time interval.
Evaluation of equality of group means was made by the appro-
priate statistical method, followed by a multiple comparison test if
needed. Bartlett’s test (Bartlett, 1937; Sokal and Rohlf, 1995) was
performed to determine if groups had equal variances. For all
parameters except organ weights, if the variances were equal,
parametric procedures were used; if not, nonparametric procedures
were used. Organ weight data was analyzed only by parametric
methods. The parametric method was the standard one-way anal-
ysis of variance (ANOVA) using the F ratio to assess signiﬁcance
(Armitage, 1971; Dunlap and Duffy, 1975). If signiﬁcant differences
among the means were indicated, additional tests were used to
determine which means were signiﬁcantly different from the con-
trol: Dunnett’s (Dunlap et al., 1981; Dunnett, 1955,1964), Williams
(Williams, 1971, 1972), or Cochran and Cox’s modiﬁed t-test
(Cochran and Cox, 1959).
The nonparametric method was the Kruskal–Wallis test
(Kruskal and Wallis, 1952, 1953) and if differences were indicated,
Shirley’s test (Shirley, 1977), Dunn’s test (Dunn, 1964), Steel’s test
(Steel, 1959) or Pairwise Comparison with Bonferroni Correction
(Games and Howell, 1976) were used to determine which means
differed from control. Bartlett’s test for equality of variance was
conducted at the 1% signiﬁcance level; all other statistical tests
were conducted at the 5% and 1% signiﬁcance levels.2.18. Compliance
These studies were conducted in accordance with the United
States Environmental Protection Agency’s (EPA) Good Laboratory
Table 3
Tissues examined microscopically.
Tissuea Weighed Tissues examined microscopically
Exposure groups Exposure groups
Control and high Low and middle
Adrenal glands X X
Aorta (thoracic) X
Bone (sternum/femur with articular surface) X
Bone marrow (femur)b X
Brain (medulla/pons, cerebrum) X X
Epididymides X X
Esophagus X
Eyes with optic nerve
Heart X X
Kidneys X Xf Xf
Lacrimal glands
Large intestine (cecum, colon and rectum X
Larynxc X
Liver X X
Lungs (with mainstem bronchi) X X X
Lymph nodes (mesenteric and thoracic) X
Mammary gland
Muscle (biceps femoris)
Nasopharyngeal tissued X
Nerve (sciatic) X
Ovaries X X
Pancreas X
Pituitary
Prostate X X
Salivary glands with submandibular lymph node X
Seminal vesicles X X
Skin
Small intestine (duodenum, ileum, jejunum) X
Spinal cord (cervical, thoracic, lumbar) X
Spleen X X
Stomach X
Testes X X
Thymus X X
Thyroid (with parathyroids) X
Trachea X
Urinary bladder X
Uterus (body/horns with cervix) X X
Zymbal’s gland
Gross lesions and tissue masses X X
Target organse (kidneys – main and recovery male rats only) X X
a These tissues were examined for animals in low and mid-dose groups which died prior to study termination.
b Qualitative examination (no differential count). Bone marrow smears were prepared and archived.
c The laryngeal mucosa was examined. Sections of the larynx examined included the epithelium covering the base of the epiglottis, the ventral pouch and the medial
surfaces of the vocal processes of the arytenoid cartilages.
d Four sections of the nasopharyngeal tissue were examined. This included sections through the nasal cavity and examinations of the squamous, transitional, respiratory
and olfactory epithelia.
e Target organs were designated by the Study Director, Pathologist and/or Sponsor based on experimental ﬁndings.
f The kidneys of all male animals in groups II and III were only examined in the BGVC and G/MTBE studies. The kidneys of male animals in the other ﬁve studies were
expected to have shown similar effects as those examined in the BGVC and G/MTBE studies.
Table 4
Exposure chamber concentrations.
Experimental group Exposure chamber concentrations – mg/m3 ± standard deviationa
TARGET BGVC G/MTBE G/EtOH G/TAME G/ETBE G/DIPE G/TBA
Group I (control) 0 0 0 0 0 0 0 0
Group II 2000 2050 ± 154 2029 ± 192 2066 ± 191 2031 ± 176 2027 ± 193 1995 ± 132 2013 ± 168
Group III 10,000 10,148 ± 739 10,099 ± 834 10,310 ± 768 10,320 ± 890 10,060 ± 691 10,030 ± 692 10,088 ± 585
Group IV 20,000 20,324 ± 1183 20,242 ± 1256 20,400 ± 1102 20,150 ± 1105 19,930 ± 1031 20,120 ± 869 20,051 ± 871
Molecular weightb 73.8 73.7 65.9 77.2 77.1 76.5 72.1
a Total hydrocarbon concentrations as determined by infrared spectroscopy.
b Average molecular weight of hydrocarbons in condensate samples.
C.R. Clark et al. / Regulatory Toxicology and Pharmacology 70 (2014) S18–S28 S23Practice Standards (US EPA, 1994a), and complied with all
appropriate parts of the Animal Welfare Act Regulations (USDA,
1989, 1991). The study also met the requirements of EPA’s guide-
lines for subchronic toxicity testing (US EPA, 1994b).3. Results
Due to the large amount of data generated in these studies only
the most signiﬁcant ﬁndings are presented here. Actual laboratory
S24 C.R. Clark et al. / Regulatory Toxicology and Pharmacology 70 (2014) S18–S28reports for these studies can be found in the Federal Docket
Management System (FDMS) at EPA-HQ-OAR-2003-0065.3.1. Chamber monitoring
Chamber distribution analyses conducted by the laboratory
during the conduct of the seven studies showed that the test sub-
stance was evenly distributed within each chamber. The mean
measured concentrations (analytical and nominal) were reason-
ably close to the targeted exposure levels for each of the gasoline
oxygenate studies. Those determined analytically are summarized
in Table 4. Also shown in the table are the average molecular
weights of the hydrocarbons contained in the different condensate
samples which can be used to calculate the approximate part per
million concentrations. The differences between measured and
nominal concentrations were typical for this type of vapor expo-
sure where a ratio of 1:1 is expected. In the TBA study, the differ-
ences between measured and nominal concentrations varied
somewhat (up to 5%) from the expected 1:1. The exact cause of
the differences was not determined but was probably a result of
a combination of slight inaccuracies in the calibration of the cham-
ber airﬂows and the calibration of the IR monitor.
Measurement of the mass median aerodynamic diameter of the
exposure atmospheres did not reveal signiﬁcant differences from
the air control chambers indicating that the atmospheres were
essentially vapor. Some particles are invariably present in chamber
atmospheres, representing background air. It is unlikely that gaso-
line vapor condensed on these particles given the volatility of these
light end vapor components and the high level of consistency in
constituent proportions demonstrated analytically from week to
week.
An estimate of the concentrations of the 18 reference hydrocar-
bons in the test substances which were generated for use in the
studies is shown in Table 5. These values, which were derived
pre-study, are expressed as area percent and intended to facilitate
comparison between studies (Henley et al., 2014). Analysis of theTable 5
Hydrocarbons detected in exposure atmospheres.
Hydrocarbons detected in test material (area perce
BGVC G/MTBE G/EtOH
Isobutane 3.6 2.2 2.2
n-Butane 15.2 11.1 11.6
Isopentane 35.1 31.0 34.0
n-Pentane 13.2 9.1 10.2
Trans-2-pentene 2.5 2.0 2.1
2-Methyl-2-butene 3.8 2.9 3.1
2,3-Dimethylbutane 1.6 0.9 2.2
2-Methylpentane 6.3 4.5 5.1
3-Methylpentane 3.6 2.6 2.9
n-Hexane 3.0 2.1 2.4
Methylcyclopentane 1.5 1.1 1.2
2,4-Dimethylpentane 1.0 0.9 1.0
Benzene 2.1 1.5 1.6
2-Methylhexane 1.1 1.0 1.1
2,3-Dimethylpentane 1.1 1.0 1.1
3-Methylhexane 1.3 1.1 1.2
Isooctane 1.3 1.2 1.3
Toluene 3.0 2.5 2.4
MTBE 21.3
EtOH 13.3
TAME
ETBE
DIPE
TBA
a Values (mean concentrations) for these 18 reference hydrocarbons were derived pre-
BGVC study. The reference hydrocarbons comprised over 81% of the total mass but arereference hydrocarbons in the test atmospheres showed a close
agreement with the neat test substance, with the exception of
ethanol.
The levels of ethanol measured in the test atmospheres were
about 20% less than measured in the neat test substance. This
was partially attributed, after the study was completed, to an inef-
ﬁciency in extracting ethanol from charcoal tubes using carbon
disulﬁde. This data demonstrated that the test animals were
exposed, as expected, to all of the major components of the test
substance in their proper proportion. The data was also consistent
from week-to-week during the study indicating stability of the test
substance and the atmosphere generation techniques (data not
shown).3.2. Mortality
All test substance-exposed main study and recovery animals in
the G/MTBE, G/EtOH, G/TAME, G/ETBE G/DIPE, and G/TBA studies
survived throughout the exposure and recovery phases. One mid-
concentration male in the BGVC study was humanely sacriﬁced
on day 69 of the exposure phase. Serology evaluation found no
infectious viral diseases; macroscopic ﬁndings were swollen fore
and hind paws, and bilateral slight discoloration of eyes and histo-
pathology revealed bilateral keratitis, unilateral anterior uveitis,
and tenosynovitis affecting all distal extremities. These gross and
histologic changes were not observed in other animals in the study
and were considered unrelated to test substance exposure. One
control male in the G/TBA study was found dead on day 71.3.3. Clinical observations
No signiﬁcant changes were observed in the animals during the
daily in chamber observations. In the weekly observations during
non-exposure periods, scattered observations such as staining of
the snout, red nasal discharge, chromodacryorrhea and lacrimation
were noted. The incidences of red nasal discharge were morent)a
G/TAME G/ETBE G/DIPE G/TBA
1.9 2.0 2.0 3.0
10.4 10.6 11.5 9.9
33.6 32.5 32.2 25.2
10.3 9.8 9.6 11.6
2.3 2.1 2.1 2.1
3.4 3.2 3.1 3.2
1.5 1.4 1.3 1.6
5.6 5.1 4.5 6.1
3.2 2.9 2.7 3.8
2.6 2.4 1.8 3.4
1.4 1.3 1.0 1.6
1.2 1.0 1.0 1.0
2.0 1.8 1.8 2.0
1.2 1.1 1.1 1.3
1.3 1.1 1.1 1.3
1.5 1.3 1.3 1.5
1.5 1.4 1.4 1.5
3.2 2.7 2.6 3.4
11.9
16.3
17.8
16.5
study (Henley et al., 2014). A total of 131 peaks were separated and identiﬁed for the
normalized to 100% to ease comparison between labs.
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females and in high concentration males in the G/DIPE study. Sig-
niﬁcant increases in the frequency of yellow anogenital staining
were seen in the high concentration G/TBA and G/TAME exposed
females and of chromodacryorrhea in high concentration G/TAME
exposed females; most of these had subsided during the recovery
period. Otherwise, the test animals were generally unremarkable
during the non-exposure periods (afternoon evaluations).3.4. Ophthalmic examinations
There were no toxicologically signiﬁcant differences in ocular
ﬁndings in most of the animals exposed to vapors of gasoline or
gasoline/oxygenate mixtures compared to the air control animals.
A slight increase in the incidence of focal retinopathy was seen in
the 20,000 mg/m3 G/ETOH exposed male animals (3 of 20) after
13 weeks of exposure, compared to air controls (0 of 20). Ocular
examination after the 4 week recovery period showed a similar
incidence in the two groups (1 of 10). The affected animal at recov-
ery was one of the three animals observed with focal retinopathy
after 13 weeks of exposure. The other two animals were termi-
nated at week thirteen. In the opinion of the attending veterinary
ophthalmologist, these abnormalities were not related to test sub-
stance exposure. A slight increase in the incidence of focal retinop-
athy also was seen in the 20,000 mg/m3 G/ETBE-exposed female
animals (1 of 20) after 13 weeks of exposure, compared to air con-
trols (0 of 20). Similar to retinopathy ﬁndings observed in the G/
EtOH study, the attending veterinary ophthalmologist concluded
the ﬁnding was not likely caused by an ocular toxicant.3.5. Body weights
There were no toxicologically signiﬁcant differences (deﬁned as
10% lower than controls) in absolute body weights in any of the
animals exposed to vapors of gasoline or gasoline/oxygenate mix-
tures compared to the air control animals. There were exposure
related differences in body weight gains in the high concentration
males and females exposed to G/EtOH. Male rats gained signiﬁ-
cantly less weight than air control animals during the initial
3 weeks of exposure. Thereafter, weekly weight gains were compa-
rable to air controls but were never sufﬁciently greater than air
controls to make up the difference from the early weeks of expo-
sure. These weights were not statistically signiﬁcantly lower than
air controls. A similar trend was seen in high concentration females
from the 2nd to the 13th week of exposure. The observed lower
body weights and weight gain for both sexes were indicators that
a maximum tolerated concentration had been reached in the study.
Exposure related decreases in body weight gains were also
observed in high concentration G/ETBE animals between intervals
0–4 and 0–13 weeks. All differences abated prior to or during the
recovery period. Fewer statistically signiﬁcant differences were
noted at the weekly intervals in the other gasoline/oxygenate
exposure studies. None of these demonstrated a treatment-related
pattern and so were not considered toxicologically signiﬁcant.3.6. Feed consumption
There were no toxicologically signiﬁcant differences in feed
consumption in any of the studies. Statistically signiﬁcant differ-
ences (increases and decreases of 15% or less from control values)
were noted at several of the weekly measurement intervals. Over-
all, these differences were not considered to have been in a treat-
ment-related pattern and were not considered attributable to
test substance exposure.3.7. Hematology and coagulation
There were no signiﬁcant treatment-related differences in
hematology and coagulation values except in the animals exposed
to G/ETBE and G/DIPE. In the G/ETBE study, there were decreased
reticulocyte counts in high concentration male and females at
the 4 week interval (which were statistically signiﬁcant in
females). These differences were not seen at the terminal interval.
A few other statistically signiﬁcant differences (such as increased
MCV in mid and high concentration males) were observed but
not in treatment related pattern, or absolute differences were
minimal.
In the G/DIPE study, there were statistically signiﬁcant
decreases (21–23%) in reticulocyte counts for the high concentra-
tion males which occurred at both exposure period intervals (4th
week and terminal) and at termination of the recovery interval.
Statistically signiﬁcant (13–17%) decreases also occurred in reticu-
locyte counts for the low and mid- concentration exposed males
but only at the 4th week interval. Similar differences did not occur
in female animals at any exposure level or during any interval but
there were statistically signiﬁcant (35–36%) decreases in absolute
monocytes for the high concentration females but only at the 4th
week and recovery intervals. Other differences (such as increases
in platelets in all exposed groups of males at the terminal interval)
were seen but not in an exposure-level related pattern and were
attributed to normal variability.
In the G/TBA study, a trend toward reductions in lymphocyte
counts, reﬂected in reduced total leukocyte counts relative to con-
trol values was seen in high concentration males at 4 and 13 weeks
of exposure and for all exposed female groups at 13 weeks. How-
ever values were close to control ranges and differences were not
exposure level-related. In the absence of evidence of immunotox-
icity (White et al., 2014) or microscopic pathology changes, these
slight differences did not appear to represent an effect of the test
substance.
3.7.1. Coagulation
There were no toxicologically signiﬁcant treatment-related dif-
ferences in coagulation values.
3.8. Clinical chemistry
There were no signiﬁcant treatment-related differences in clin-
ical chemistry ﬁndings in the majority of the studies, with the
exception of animals exposed to G/ETBE and G/TBA. During the
4th week of exposure in the G/ETBE study, decreased aspartate
aminotransferase values in high concentration males and females,
decreased lactate dehydrogenase values in all exposed males and
females, and decreased creatine kinase values in high concentra-
tion females were observed. These differences were not seen at
the terminal interval.
In the G/TBA study, slight to moderate increases in serum cho-
lesterol in the mid- and high-concentration males (21–34% higher
after 4 and/or 13 weeks of exposure) were observed. After 4 weeks
of recovery the values were similar to controls (within 12%) and no
liver pathology was seen. Statistically signiﬁcant decreases were
also seen in lactate dehydrogenase, sorbitol dehydrogenase and
creatine kinase values in one or more exposed groups. No corre-
sponding microscopic pathology changes were seen.
3.9. Organ weights
There were no toxicologically signiﬁcant differences in organ
weights and brain measurements in animals exposed to BGVC or
G/DIPE. Signiﬁcant increases in kidney weights were observed in
mid- and high concentration males exposed to G/MTBE, G/EtOH,
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to G/ETBE, and mid- and high concentration females exposed to
G/MTBE. These kidney weights were not signiﬁcantly different
when measured at the end of the recovery interval except in the
G/TBA exposed males. Statistically signiﬁcant changes were seen
in several other organ weights at various intervals in the studies.
However, these were not seen in an exposure level related pattern
and/or the absolute differences were minimal and there were no
corresponding histopathology ﬁndings.3.10. Pathology – macroscopic ﬁndings
No gross abnormalities related to test substance exposure were
evident on necropsy examination of animals in the BGVC, G/MTBE,
G/EtOH, G/DIPE, and G/TBA exposure groups. The macroscopic
lesions noted were similar to those routinely encountered in ani-
mals of this age and species or were represented by individual ani-
mals and considered incidental ﬁndings. In G/TAME exposed
animals, six of 20 high concentration females (3 terminal, 3 recov-
ery) had foci of red or tan discoloration of lungs which were not
seen in control females, but which were observed in several control
males. Since no microscopic changes were correlated with these
observations, it was concluded that they were not likely related
to test substance exposure. Two mid concentration and 5 high con-
centration G/ETBE exposed animals had exposure dependent inci-
dence of bilateral renal foci of red discoloration at terminal
sacriﬁce, which was not observed in control or low concentration
animals. Some individual control and low concentration females
had similar foci.3.11. Pathology – microscopic ﬁndings
Microscopic ﬁndings that were considered exposure related
were found in the kidneys of male animals in all of the gasoline
and gasoline/oxygenate exposure studies. In the BGVC and G/MTBE
studies, male rats exposed at all exposure levels had eosinophilic
hyaline granules within the cytoplasm of renal proximal convo-
luted tubular epithelial cells. The degree of cytoplasmic granula-
tion varied in an exposure-level dependent manner. Most 10,000
and 20,000 mg/m3 exposed males also had evidence of tubular
regeneration (basophilic tubules) at a higher incidence and sever-
ity compared to control males. Several animals among each ofTable 6
Summary of treatment related effects.
BGVC G/MTBE G/EtOH
Red nasal discharge 20,000 mg/m3 M,F WNL WNL
Decreased body
weight gain
WNL WNL 20,000
Food consumption WNL WNL WNL
Functional
observational
battery
WNL WNL WNL
Motor activity WNL WNL WNL
Increased cholesterol WNL WNL WNL
Decreased
reticulocyte counts
WNL WNL WNL
Increased kidney
weights
WNL 2000, 10,000 and
20,000 mg/m3 M,F
10,000
20,000
Hydrocarbon
nephropathy
2000, 10,000 and
20,000 mg/m3 Ma
2000, 10,000 and
20,000 mg/m3 Ma
20,000
Neuropathology WNL WNL WNL
M = males; F = females; WNL = within normal limits.
a Not seen at recovery interval.
b Terminal interval and recovery animals at lower exposure levels were not evaluatedthese exposure groups had corticomedullary intraluminal tubular
granular casts. Similar changes were not evident in females having
test substance exposure or in control animals. Mallory-Heidenhain
(MH) staining of renal tissue of male rats showed red staining of
granular material within proximal tubular epithelium. Minimal
staining was apparent in control males and slight to moderate
staining was present in exposed female animals.
The 20,000 mg/m3 exposed males in the BGVC and G/MTBE
studies, sacriﬁced following a 4-week recovery period, had near
complete resolution of the relevant histologic changes except the
effect on the basophilic cortical tubules was unresolved. A single
animal exposed to BGVC and two exposed to G/MTBE had granular
casts and hyaline granules appreciable with routine (hematoxylin
and eosin) stain. Because these renal ﬁndings were expected, and
have been fully investigated during prior testing with gasoline test
substances (Benson et al., 2011), no further examinations of ani-
mals from the recovery group were made in the studies of other
gasoline oxygenates.
In all of the gasoline/oxygenate exposure studies, histopatho-
logic changes similar to those seen in the BGVC and G/MTBE stud-
ies in the high exposure level males were observed. Because these
changes were expected, animals at the low and middle exposure
levels were not examined, however, they would have been
expected to show similar effects in a treatment-related pattern,
particularly where increases in kidney weights were seen.
The only other microscopic ﬁnding of toxicologic signiﬁcance
was in the BGVC study. Some of the high exposure level male
and female rats had eosinophilic material within the nasolacrimal
duct lumen at the Terminal sacriﬁce. This ﬁnding was considered
to correlate with the increase in red nasal discharge noted previ-
ously in this group of test animals. Similar changes were not evi-
dent in control animals.4. Discussion and conclusions
A summary of the treatment related effects noted in the seven
studies are presented in Table 6 which identiﬁes those exposure
concentrations where adverse effects were noted. Thirteen weeks
of inhalation exposure of rats to vapor condensates of either
gasoline or gasoline combined with fuel oxygenates resulted
in hydrocarbon nephropathy in male animals. The microscopic
lesions observed were consistent with changes associated withG/TAME G/ETBE G/DIPE G/TBA
WNL WNL 20,000 mg/
m3 M,F
WNL
mg/m3 M,F WNL 20,000 mg/
m3 F
WNL WNL
WNL WNL WNL WNL
WNL WNL WNL WNL
WNL WNL WNL WNL
WNL WNL WNL 10,000 and
20,000 mg/m3 M
WNL 20,000 mg/
m3 F
20,000 mg/
m3 M
WNL
and
mg/m3 Mb
20,000 mg/
m3 M
20,000 mg/
m3 M
WNL 10,000 and
20,000 mg/m3 M
mg/m3 Mb 20,000 mg/
m3 Mb
20,000 mg/
m3 Mb
20,000 mg/
m3 Mb
20,000 mg/m3 Mb
WNL WNL WNL WNL
.
Table 7
Summary of no observed adverse effect levels.
No observed adverse effect levels (NOAEL) in mg/m3
BGVC G/MTBE G/EtOH G/TAME G/ETBE G/DIPE G/TBA
NOAEL 10,000 None 10,000 10,000 10,000 10,000 2000
Basis Red nasal
discharge
Increased kidney
weights
Decreased body
weight gain
Increased kidney
weights
Decreased body weight gain,
hematology
Hematology, red nasal
discharge
Increased
cholesterol
NOAEL = No observable adverse effect level based on effects other than male hydrocarbon nephropathy.
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lysosomes. This change has been well documented to be unique
to male rats exposed gasoline hydrocarbons (Benson et al., 2011)
as well as to a variety of other chemicals (Alden, 1986) and has
been generally accepted not to be relevant to human risk (US
EPA, 1991).
Exposure to both BGVC and G/DIPE vapors resulted in slight but
reversible increases in red nasal discharge in animals exposed to
20,000 mg/m3 of vapor. Therefore, the 10,000 mg/m3 exposure
level (excluding male rat nephropathy) was considered a no obser-
vable adverse effect level (NOAEL – i.e. the highest level at which
no adverse effects were observed) (Table 7). Condensates of MTBE
in gasoline resulted in slight but reversible increases in kidney
weights in all female groups. No corresponding histopathologic
changes were noted in kidneys. On this basis, none of the exposure
levels was considered a NOAEL. There was no effect on kidney
weights in Sprague Dawley rats exposed to the same concentra-
tions of G/MTBE for 24 months (Benson et al., 2011).
Vapor condensates of G/EtOH resulted in decreased body
weight gains in high concentration males and females. Since the
changes in body weight gain and kidney weights were absent at
the recovery interval the 10,000 mg/m3 exposure level was consid-
ered to be the NOAEL. Decreased body weight gains were also
observed in rat reproductive toxicity studies (Gray et al., 2014)
and in rat developmental toxicity studies (Roberts et al., 2014b)
but only at exposure levels of G/EtOH of 20,000 mg/m3.
The NOAEL for animals in the G/TAME study was considered to
be 10,000 mg/m3, based on increased incidences of anogenital
staining, red nasal discharge and chromodacryorrhrea noted in
high concentration animals. There was reversible hematology
and clinical chemistry parameters in high concentration G/ETBE
animals and mild but reversible decreases in body weight gains
in high concentration females, therefore 10,000 mg/m3 (excluding
male rat nephropathy) was considered the NOAEL for subchronic
toxicology parameters.
Exposure to vapor condensates of G/DIPE resulted in increased
red nasal discharge and slight, non-reversible decreases in reticulo-
cyte values (at the 4th week and terminal and recovery intervals)
in the male animals exposed to 20,000 mg/m3 of vapor. Therefore,
the 10,000 mg/m3 exposure level (excluding male rat nephropa-
thy) was considered a NOAEL. In the G/TBA studies, exposures
caused increased yellow anogenital staining and increases in cho-
lesterol values in male and/or female animals exposed to
20,000 mg/m3 of vapor. The cholesterol differences were also noted
in the 10,000 exposed animals. Therefore, the 2000 mg/m3 expo-
sure level (excluding male rat nephropathy) was considered a
NOAEL.
The NOAELs for exposure to all of the gasoline/oxygenate con-
densates was similar to that for exposure to gasoline emissions
alone (10,000 mg/m3) with the exception of G/MTBE and G/TBA.
Since the endpoints responsible for these lower NOAELs (increased
kidney weights and increased cholesterol) were not considered
toxicologically signiﬁcant, it can be concluded that the addition
of the oxygenates evaluated in this study did not signiﬁcantly alter
the subchronic toxicity of evaporative emissions compared to thatof gasoline alone. These no effect concentrations are signiﬁcantly
higher than those typically encountered by humans which can
reach 10–100 ppm total hydrocarbon vapor while refueling, partic-
ularly prior to the implementation of vapor recovery devices both
within the automobile and the fuel pump (Zielinska et al., 2012).
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